Wells Fargo analyst Nathan Treybeck raised the firm’s price target on Procept BioRobotics to $57 from $47 and keeps an Overweight rating on the shares. The firm notes Procept BioRobotics reported Q4 sales in line with pre-announcement, though margins missed on HQ move disruption and investment pull forward. 2024 revenue guide of $210M was $5M above Street. Management sounded more bullish on bulk IDN purchases, though not in guide, Wells adds.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on PRCT:
- PROCEPT BioRobotics Reports Fourth Quarter and Full Year 2023 Results
- PROCEPT BioRobotics to Present at the 44th Annual TD Cowen Health Care Conference in Boston
- Procept BioRobotics price target raised to $58 from $42 at Piper Sandler
- Procept BioRobotics price target raised to $47 from $44 at Wells Fargo
- PROCEPT BioRobotics® Announces Preliminary Fourth Quarter Revenue of $43.3 million to $43.6 million
